Ruijie Chen

Ruijie Chen

Auto-generated profile, based on publicly available information

Ruijie Chen

Department of Pharmacy, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Drug Delivery
Verified
Journal Article
Open access
LKLongfa Kou
Longfa Kou
SXShuyi Xiao
Shuyi Xiao
RSRui Sun
Rui Sun
SBShihui Bao
Shihui Bao
QYQing Yao
Qing Yao
RCRuijie Chen
Ruijie Chen
Osteoarthritis (OA) is a progressive and degenerative disease, which is no longer confined to the elderly. So far, current treatments are limited to symptom relief, and no valid OA disease-modifying drugs are available. Additionally, OA relative joint is challenging for drug delivery, since the drugs experience rapid clearance in joint, showing a poor bioavailability. Existing therapeutic drugs, like non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are not conducive for long-term use due to adverse effects. Though supplementations, including chondroitin sulfate and glucosamine, have shown beneficial effects on joint tissues in OA, their therapeutic use is still debatable. New emerging agents, like Kartogenin (KGN) and Interleukin-1 receptor antagonist (IL-1 ra), without a proper formulation, still will not work. Therefore, it is urgent to establish a suitable and efficient drug delivery system for OA therapy. In this review, we pay attention to various types of drug delivery systems and potential therapeutic drugs that may escalate OA treatments.

19 July 2018 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
LKLongfa Kou
Longfa Kou
RSRui Sun
Rui Sun
VGVadivel Ganapathy
Vadivel Ganapathy
QYQing Yao
Qing Yao
RCRuijie Chen
Ruijie Chen
Introduction: Transporters in the plasma membrane have been exploited successfully for the delivery of drugs in the form of prodrugs and nanoparticles. Organic cation/carnitine transporter 2 (OCTN2, SLC22A5) has emerged as a viable target for drug delivery. OCTN2 is a Na+-dependent high-affinity transporter for L-carnitine and a Na+-independent transporter for organic cations. OCTN2 is expressed in the blood-brain barrier, heart, liver, kidney, intestinal tract and placenta and plays an essential role in L-carnitine homeostasis in the body. Areas covered: In recent years, several studies have been reported in the literature describing the utility of OCTN2 to enhance the delivery of drugs, prodrugs and nanoparticles. Here we summarize the salient features of OCTN2 in terms of its role in the cellular uptake of its physiological substrate L-carnitine in physiological and pathological context; the structural requirements for recognition and the recent advances in OCTN2-targeted drug delivery systems, including prodrugs and nanoparticles, are discussed. Expert opinion: This transporter has great potential to be utilized as a target for drug delivery to improve oral absorption of drugs in the intestinal tract. It also has potential to facilitate the transfer of drugs across the biological barriers such as the blood-brain barrier, blood-retinal barrier, and maternal-fetal barrier.

1 October 2019 in Phytomedicine
Verified
Journal Article
Closed access
HCHongjin Chen
Hongjin Chen
YZYali Zhang
Yali Zhang
WZWenxin Zhang
Wenxin Zhang
HLHui Liu
Hui Liu
CSChuchu Sun
Chuchu Sun
GLGuang Liang
Guang Liang

1 April 2018 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
WYWeijian Ye
Weijian Ye
XLXiaoji Lin
Xiaoji Lin
YZYouting Zhang
Youting Zhang
YXYouxiao Xu
Youxiao Xu
RSRui Sun
Rui Sun
RCRuijie Chen
Ruijie Chen

1 January 2019 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
ZWZhe Wang
Zhe Wang
WSWei Sun
Wei Sun
ZLZheng-Feng Lin
Zheng-Feng Lin
RSRui Sun
Rui Sun
CHCheng-Ke Huang
Cheng-Ke Huang
RCRui-Jie Chen
Rui-Jie Chen

1 January 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
CNChao Niu
Chao Niu
WYWeijian Ye
Weijian Ye
XCXiao Cui
Xiao Cui
JSJia Sun
Jia Sun
SXShuyi Xiao
Shuyi Xiao
RCRuijie Chen
Ruijie Chen